GlassScriptPhysician profile
Nancy A Tompkins
NPI 1922554146
$26,858.52
in general payments reported to CMS, 2019-2025
14 companies · $8,343 in 2025
The $8,343 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.35 · 2022: $3,683 · 2023: $8,606 · 2024: $6,213 · 2025: $8,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $1,338 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,730.00 |
| Food and Beverage | $1,337.58 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $25,427.01 | 2022-2025 | Omnipod, Omnipod |
| Corcept Therapeutics | $622.72 | 2023-2025 | Korlym |
| Abbott Laboratories | $183.24 | 2021-2025 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $110.53 | 2025 | Twiist |
| Astellas Pharma US INC | $94.99 | 2023 | |
| Lilly USA, LLC | $93.74 | 2024-2025 | Mounjaro |
| Dexcom, INC. | $66.19 | 2022-2025 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $65.00 | 2023 | Qutenza |
| Sumitomo Pharma America, INC. | $53.26 | 2023-2025 | Gemtesa |
| Madrigal Pharmaceuticals | $36.46 | 2025 | Rezdiffra |
| Medtronic, INC. | $31.52 | 2023 | Minimed 780g |
| Amgen INC. | $29.26 | 2022-2024 | Otezla, Repatha |
| Novo Nordisk INC | $22.66 | 2025 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $21.94 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Tompkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.